Results 191 to 200 of about 107,123 (321)

RB1 Gene [PDF]

, 2020
openaire   +1 more source

Intramolecular Matere Bonds in Isostructural Rubidium (18‐Crown‐6) Pertechnetate and Perrhenate Dimers

European Journal of Inorganic Chemistry, Volume 29, Issue 16, 4 June 2026.
Two rubidium cations that are not fully encapsulated by 18‐crown‐6 are bridged by two pertechnetate units to form a dimer. These two pertechnetate units are nearly linearly aligned to each other to form Matere bonds (MaBs), a type of noncovalent σ‐hole interaction.
Clarence Yong, Sergi Burguera, Dennis Grödler, Christoph Lenting, Hakim Ibrahim, Mathias S. Wickleder, Antonio Frontera, Erik Strub   +7 more
wiley   +1 more source

RB1 Positive [PDF]

, 2020
openaire   +1 more source

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

RB1 Negative [PDF]

, 2020
openaire   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, Volume 20, Issue 6, Page 1535-1555, June 2026.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, Volume 20, Issue 6, Page 1591-1611, June 2026.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

RB1 goes global [PDF]

Nature Reviews Molecular Cell Biology, 2005
openaire   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

One hotspot <i>RB1</i> mutation disrupt <i>RB1</i> function founded in a Chinese patient. [PDF]

Front Oncol
Liu Y, Ren K, He F, Deng Y, Zhou Y, Huang X, Zhang L.   +6 more
europepmc   +1 more source